<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="1309">
  <stage>Registered</stage>
  <submitdate>4/08/2006</submitdate>
  <approvaldate>25/08/2006</approvaldate>
  <actrnumber>ACTRN12606000373572</actrnumber>
  <trial_identification>
    <studytitle>Outpatient Ifosfamide, Etoposide plus Rituximab (R-IE) for salvage in patients &gt; 60 years with relapsed or refractory CD20 positive diffuse large B-cell lymphoma who are not candidates for stem cell transplant study</studytitle>
    <scientifictitle>A phase IV study to evaluate the treatment response (Complete Response [CR]and Partial Response [PR] of out-patient Ifosfamide, Etoposide plus Rituximab (R-IE) for salvage in patients &gt;60 years with relapsed or refractory CD20 positive diffuse large B-cell lymphoma who are not candidates for stem cell transplant</scientifictitle>
    <utrn />
    <trialacronym>R-IE</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Relapsed or refractory CD20 positive diffuse large B-cell lymphoma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Rituximab 375 mg/m2 iv on day 1
Ifosfamide 5,000 mg/m2 iv in equally divided doses over 3 days (days 1-3)
Etoposide 100 mg/m2 iv daily for days 1 to 3
Pegfilgrastim 6 mg subcutaneous (SC) on day 4 
6 cycles (21 days in each cycle)</interventions>
    <comparator />
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To evaluate overall treatment response (Complete Response (CR) and Partial Response(PR)) of an outpatient-based fractionated salvage regimen consisting of ifosfamide, etoposide plus rituximab (R-IE) given every three weeks in patients &gt; 60 years with relapsed or refractory CD20 positive diffuse large B-cell lymphoma and who are not considered eligible for stem cell transplantation. </outcome>
      <timepoint>To be assessed after Cycle 3 &amp; 6.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To evaluate overall survival</outcome>
      <timepoint>Every 3 months following completion of 6 cycles of therapy for 5 years.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To evaluate event free survival</outcome>
      <timepoint>Every 3 months following completion of 6 cycles of therapy for 5 years.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To evaluate the safety profile</outcome>
      <timepoint>After each cycle of therapy</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To evaluate the haematological toxicity (grades 3/4 neutropenia and thrombocytopenia).</outcome>
      <timepoint>After each cycle of therapy</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Eastern Oncology Co-operative Group (ECOG) performance status 0 to 2. 2. Relapsed or progressive Cluster Designation 20 (CD20) positive diffuse large B-cell lymphoma including induction failures to first-line anthracycline-containing regimens and not usually considered eligible for high dose chemotherapy and stem cell transplantation. 3. Able to give written informed consent. 4. Life expectancy ³ 3 months</inclusivecriteria>
    <inclusiveminage>60</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. History of severe cardiac, hepatic, respiratory, or renal disease. 2. Poor renal function (serum creatinine &gt; 150 µmol/L or 1.5-2.0 x Upper Limit Normal (ULN), poor hepatic function (bilirubin &gt;30 µmol/L or &gt;1.5x ULN; transaminases&gt;2.5 x ULN) unless these abnormalities are related to lymphoma. 3. Poor bone marrow reserve as defined by neutrophils &lt;1.5 x 109/L or platelets &lt;100 x 109/L unless related to bone marrow infiltration. 4. Pregnant women or breast-feeding mothers. 5. Known hypersensitivity to E coli proteins, or with known anaphylaxis or IgE-mediated hypersensitivity to murine proteins, or to any component of the drugs being used. 6. Unable to provide written informed consent.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3 / Phase 4</phase>
    <anticipatedstartdate>1/05/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>40</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Roche</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Switzerland</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Roche</fundingname>
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Amgen &amp; Baxter</fundingname>
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>Amgen &amp; Baxter</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Patients with relapsed or refractory lymphoma require initial salvage chemotherapy to control their disease. One type of salvage chemotherapy is Rituximab, Ifosfamide and Etoposide (R-IE) given for six cycles administered every 21 days, followed by two additional doses of Rituximab at intervals of 21 days. Ifosfamide and Etopside are given on days 1 to 3 and Rituximab is given on day 1. On the day following each cycle of the R-IE therapy (day 4) a single injection under the skin of pegfilgrastim is given to prevent the white blood cell count from falling too low and therefore reduce the number of infections the patient may experience.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Westmead Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>25/11/2005</ethicapprovaldate>
      <hrec>2005/9/4.7(2186)</hrec>
      <ethicsubmitdate />
      <ethiccountry />
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Concord Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec>CH62/6/2006-005</hrec>
      <ethicsubmitdate />
      <ethiccountry />
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Mark Hertzberg</name>
      <address>Deparment of Clinical Haematology
Westmead Hospital
Westmead NSW 2145</address>
      <phone>+61 2 98457610</phone>
      <fax>+61 2 96892331</fax>
      <email>mark_hertzberg@wmi.usyd.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Angela Bayley</name>
      <address>Deparment of Clinical Haematology
Westmead Hospital
Westmead NSW 2145</address>
      <phone>+61 2 98457219</phone>
      <fax>+61 2 96893700</fax>
      <email>Angelab@icpmr.wsahs.nsw.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>